In Corporate Livewire‘s June 2013 Round Table “Biotech & Pharmaceutical,” Dr. Gregory Bell and other leading experts discuss changes and analyze the effects they will have in the industry.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...
